Ämnen: Industri, tillverkning

Ny studie visar överlevnadsfördel för Faslodex (fulvestrant) jämfört med Arimidex (anastrozol) hos kvinnor med avancerad östrogenpositiv bröstcancer

16 September 2015 08:30

AstraZeneca tillkännagav i dag publiceringen av viktiga data om total överlevnad (overall survival OS) från FIRST*-studien, en randomiserad, öppen multicenterstudie i fas II där man jämför första linjens behandling med östrogenreceptorantagonisten Faslodex® (fulvestrant) 500 mg mot aromatashämmaren Arimidex® (anastrozol), hos postmenopausala kvinnor med ER-positiv bröstcancer i avancerat stadium.

ASTRAZENECA TO PRESENT COMPREHENSIVE DATA FROM ITS DIABETES PORTFOLIO AND PRE-CLINICAL RESEARCH

11 September 2015 09:03

11 September 2015
AstraZeneca today announced that 54abstracts from the company’s research and development in diabetes will be presented at the 51st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden, 14-18 September 2015.
The presentations will include data on a number of approved products for the treatment of type 2 diabetes, including Forxiga®

ASTRAZENECA PURCHASES US BIOLOGICS MANUFACTURING FACILITY TO SUPPORT GROWING PIPELINE

11 September 2015 08:01

AstraZeneca today added to its biologics manufacturing capability in the US with the purchase of a high-tech biologics bulk manufacturing facility from Amgen Inc. Over time, the LakeCentre facility, located in Boulder, Colorado will increase manufacturing and production capacity to support the company’s extensive portfolio of biologics medicines.

Unikt samarbete mellan industri och akademi kring avancerad utrustning ger nya möjligheter att angripa svåra sjukdomar

9 September 2015 13:00

AstraZeneca, Göteborgs universitet och Chalmers meddelar i dag att man ingått ett nytt samarbete kring en avancerad utrustning for masspektrometri som gör att man på ett bättre sätt kan studera hur molekyler interagerar på cellulär nivå.

AstraZeneca to update on leading lung cancer portfolio at WCLC 2015

4 September 2015 09:04

Data will be reported from across AstraZeneca’s industry-leading lung cancer portfolio at the World Conference on Lung Cancer (WCLC) 2015, beginning this weekend in Denver, Colorado.

US FDA approves expanded indication for BRILINTA to include long-term use in patients with a history of heart attack

3 September 2015 22:49

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved BRILINTA® (ticagrelor) tablets at a new 60mg dose to be used in patients with a history of heart attack beyond the first year..

Positive phase III results demonstrate efficacy of antibiotic medicine CAZ-AVI in complicated urinary tract infections

2 September 2015 13:08

​AstraZeneca today announced positive topline results from RECAPTURE 1and RECAPTURE 2, the pivotal Phase III studies evaluating the antibiotic, CAZ-AVI (ceftazidime-avibactam), as a treatment for adult hospitalised patients with complicated Urinary Tract Infections (cUTI), including pyelonephritis.

Ny studie visar på förbättrad följsamhet till behandling efter hjärtinfarkt med hjälp av mobilapp

2 September 2015 09:10

Idag presenterades resultaten från den svenska SUPPORT studien som undersökt effekten på följsamhet och förebyggande insatser efter hjärtinfarkt (sekundärprevention) med hjälp av en mobiltelefonapplikation (”app”).

AstraZeneca enters license agreement with Daiichi Sankyo for development and commercialisation of FluMist in Japan

2 September 2015 08:02

AstraZeneca today announced that its global biologics research and development arm, MedImmune, has entered an agreement granting Daiichi Sankyo Company, Ltd. (Daiichi Sankyo) an exclusive license to develop and commercialise FluMist® Quadrivalent in Japan.

Ticagrelor (BRILIQUE) i samband med kranskärlskirurgi ger färre blödningskomplikationer jämfört med clopidogrel

1 September 2015 10:00

En ny studie som presenteradesden 1 september under den Europeiska hjärtläkarkongressen i London (ESC) visar att ticagrelor jämfört med clopidogrel minskar risken för allvarliga blödningar i samband med kranskärlskirurgi.

AstraZeneca och Valeant i samarbete om brodalumab

1 September 2015 08:11

AstraZeneca fortsätter att skärpa fokus på sina viktigaste terapiområden och ett samarbete med en expert inom dermatologi förväntas snabba på utvecklingen av brodalumab för patienter med psoriasis och tillgodose ett betydande ouppfyllt behandlingsbehov

Subgruppsanalys från PEGASUS-TIMI 54-studien visar vikten av fortsatt underhållsbehandling med BRILINTA/BRILIQUE i mer än ett år efter en hjärtinfarkt

31 Augusti 2015 16:16

Data som presenterades vid European Society of Cardiologys kongress 2015 betonar behovet av långsiktig sekundärprevention för att förhindra nya hjärt-kärlhändelser

AstraZeneca to present further research into long-term prevention of cardiovascular events for patients with a history of heart attack at ESC Congress 2015

29 Augusti 2015 09:32

Over 20 scientific abstracts from AstraZeneca’s cardiovascular and metabolic disease portfolio will be presented at this year’s European Society of Cardiology (ESC) Congress 2015 in London, including five oral presentations.

AstraZeneca and Peregrine Pharmaceuticals to collaborate on immuno-oncology combination clinical trial

24 Augusti 2015 08:07

AstraZeneca today announced that it has entered into a clinical trial collaboration with Peregrine Pharmaceuticals, Inc. to evaluate the safety and efficacy of Peregrine’s investigational phosphatidylserine (PS)-signalling pathway inhibitor, bavituximab, in combination with AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736). The planned Phase I/Ib trial wil

AstraZeneca appoints Dr Sean Bohen as Executive Vice President of Global Medicines Development and Chief Medical Officer

24 Augusti 2015 08:06

AstraZeneca today announced the appointment of Sean Bohen MD, PhD, as Executive Vice President of Global Medicines Development and Chief Medical Officer. He will join the company on 15 September.
Dr. Bohen will be responsible for driving the progress of AstraZeneca’s portfolio of small molecules and biologics investigational medicines through late-stage development to regulatory approval. As C

Medimmune enters into strategic cancer vaccine collaboration and license agreement with Inovio Pharmaceuticals

10 Augusti 2015 09:02

​Agreement includes clinical-stage INO-3112 HPV cancer vaccine and preclinical collaboration to develop additional cancer vaccine candidates

AstraZeneca and Heptares Therapeutics enter agreement to develop novel immuno-oncology treatments

6 Augusti 2015 08:01

AstraZeneca and Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation, today announced that they have entered into a licensing agreement.

Medimmune and Mirati Therapeutics partner on immuno-oncology combination in lung cancer

5 Augusti 2015 08:03

AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into an exclusive clinical trial collaboration with Mirati Therapeutics, Inc., an oncology company focusing on genetic and epigenetic drivers of cancer.

AstraZeneca and Isis Pharmaceuticals to discover and develop antisense drugs for cardiovascular, metabolic and renal diseases

3 Augusti 2015 08:02

AstraZeneca and Isis Pharmaceuticals, Inc. today announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. The new collaboration builds on a broad existing relationship between the two companies and supports AstraZeneca’s strategic approach in these therapeutic areas using novel RNA-targeted treatments. It also enables Isis Ph

Resultat AstraZeneca PLC första halvåret 2015

30 Juli 2015 08:04

Utvecklingen i sammandrag
Totala intäkter för första halvåret ökade med 1 %; Bruttomarginalen för kärnverksamheten över 83%, ökning med 1 procentenhet
Starka totala intäkter, gynnat av intäkter från externa samarbeten, stöttar tilltagande investeringar i FoU för att utveckla forskningsportföljen; FoU-investeringarna ökade med 24 % under första halvåret
Effektivitetsprogram avseende kärnve